Sponsors (4)
The bill gives regulators stronger visibility into drug supply chains to speed recalls and reduce shortages—benefiting patients and health systems—but imposes new reporting and disclosure requirements that raise costs, proprietary risks, and compliance burdens that will fall hardest on smaller suppliers and could raise prices or reduce market diversity.
Patients (especially those with chronic conditions) and hospitals gain faster identification and response to drug shortages and contaminated products because FDA and firms will have supplier-level and origin data enabling quicker recalls and mitigation.
Americans benefit from more secure and resilient medicine supplies because regulators can identify single‑supplier risks and better target inspections or mitigation to prevent systemic supply failures.
Patients, hospitals, and taxpayers may face lower long‑run costs from fewer shortages, delays, and substitute therapies as improved supply transparency reduces health‑system disruptions.
Drug makers, distributors, and suppliers—particularly smaller firms—face substantial new compliance costs and administrative burdens from more frequent, detailed reporting, tracking, and labeling requirements, which could reduce margins and competitiveness.
Smaller manufacturers and API suppliers may struggle with the new cadence and data/tracking demands, potentially reducing production, causing market exits or consolidation, and thereby weakening supply diversity.
Public reporting of supplier identities, facility identifiers, or locations raises proprietary and competitive‑harm concerns (and potential security risks) for manufacturers and supply chains if protections are inadequate.
Based on analysis of 3 sections of legislative text.
Requires detailed supplier identity and quantity reporting for all APIs and in-process materials and mandates manufacturer identification on drug packaging and API certificates.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes.
Introduced April 16, 2026 by Doris Matsui · Last progress April 16, 2026
Requires drug manufacturers to report detailed supplier identities and quantities for every active pharmaceutical ingredient (API), intermediate, and in-process material used to make a drug, on a Secretary-specified schedule (more often than annually, up to quarterly). Requires drug packages (and API certificates) to display the original manufacturer's name, place of business, and a Secretary-designated unique facility identifier, and requires labeling to identify original and subsequent API manufacturers plus the packer/distributor, with limited regulatory flexibility for alternative placements or electronic disclosures.